Intracerebral hemorrhage risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 8: | Line 8: | ||
==Risk factors== | ==Risk factors== | ||
Common risk factors in the development of [[intracerebral hemorrhage|intracerebral hemorrhage (ICH)]] include:<ref name=Huhtakangas>Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemor- rhage: a longitudinal population-based study. Stroke. 2011;42:2431– 2435. doi: 10.1161/STROKEAHA.111.615260.</ref><ref name=Rådberg> Rådberg JA, Olsson JE, Rådberg CT. Prognostic parameters in sponta- neous intracerebral hematomas with special reference to anticoagulant treatment. Stroke. 1991;22:571–576. doi: 10.1161/01.STR.22.5.571.</ref><ref name=Flaherty> Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–121. doi: 10.1212/01.wnl.0000250340.05202.8b.</ref><ref name="pmid12843354">{{cite journal| author=Ariesen MJ, Claus SP, Rinkel GJ, Algra A| title=Risk factors for intracerebral hemorrhage in the general population: a systematic review. | journal=Stroke | year= 2003 | volume= 34 | issue= 8 | pages= 2060-5 | pmid=12843354 | doi=10.1161/01.STR.0000080678.09344.8D | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12843354 }} </ref> | Common risk factors in the development of [[intracerebral hemorrhage|intracerebral hemorrhage (ICH)]] include:<ref name=Huhtakangas>Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemor- rhage: a longitudinal population-based study. Stroke. 2011;42:2431– 2435. doi: 10.1161/STROKEAHA.111.615260.</ref><ref name=Rådberg> Rådberg JA, Olsson JE, Rådberg CT. Prognostic parameters in sponta- neous intracerebral hematomas with special reference to anticoagulant treatment. Stroke. 1991;22:571–576. doi: 10.1161/01.STR.22.5.571.</ref><ref name=Flaherty> Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–121. doi: 10.1212/01.wnl.0000250340.05202.8b.</ref><ref name="pmid12843354">{{cite journal| author=Ariesen MJ, Claus SP, Rinkel GJ, Algra A| title=Risk factors for intracerebral hemorrhage in the general population: a systematic review. | journal=Stroke | year= 2003 | volume= 34 | issue= 8 | pages= 2060-5 | pmid=12843354 | doi=10.1161/01.STR.0000080678.09344.8D | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12843354 }} </ref><ref name="pmid17962600">{{cite journal| author=Bos MJ, Koudstaal PJ, Hofman A, Breteler MM| title=Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. | journal=Stroke | year= 2007 | volume= 38 | issue= 12 | pages= 3127-32 | pmid=17962600 | doi=10.1161/STROKEAHA.107.489807 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17962600 }} </ref><ref name="pmid23077009">{{cite journal| author=Hackam DG, Mrkobrada M| title=Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. | journal=Neurology | year= 2012 | volume= 79 | issue= 18 | pages= 1862-5 | pmid=23077009 | doi=10.1212/WNL.0b013e318271f848 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23077009 }} [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23449782 Review in: Evid Based Ment Health. 2013 May;16(2):54] </ref> | ||
* [[Hypertension]] | * [[Hypertension]] | ||
* [[Anticoagulation]] medication | * [[Anticoagulation]] medication | ||
| Line 17: | Line 17: | ||
**[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation (DIC)]] | **[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation (DIC)]] | ||
**[[Hemophilia]]s | **[[Hemophilia]]s | ||
* Acquired qualitative or quantitative platelet abnormalities | * Acquired qualitative or quantitative [[platelet abnormalities]] | ||
* [[Chronic kidney disease]] (CKD) | ** [[Chronic kidney disease]] (CKD) | ||
*[[Selective serotonin reuptake inhibitors]] | ** [[Selective serotonin reuptake inhibitors]] | ||
* Embolic [[stroke]]s | * Embolic [[stroke]]s | ||
* [[Sickle Cell Anemia]] | * [[Sickle Cell Anemia]] | ||
Revision as of 14:45, 29 November 2016
|
Intracerebral hemorrhage Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage (2015) |
|
AHA/ASA Guideline Recommendation for the Primary Prevention of Stroke (2014) |
|
Case Studies |
|
Intracerebral hemorrhage risk factors On the Web |
|
American Roentgen Ray Society Images of Intracerebral hemorrhage risk factors |
|
Risk calculators and risk factors for Intracerebral hemorrhage risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mehrsefat, M.D. [2]
Overview
Common risk factors in the development of intracerebral hemorrhage (ICH) include hypertension, anticoagulation medication(warfarin), acquired or congenital coagulation factor disorder (such as vitamin K deficiency, liver disease, disseminated Intravascular Coagulation (DIC), and hemophilias), platelet abnormalities, embolic strokes, and Sickle Cell Anemia.[1][2][3]
Risk factors
Common risk factors in the development of intracerebral hemorrhage (ICH) include:[1][2][3][4][5][6]
- Hypertension
- Anticoagulation medication
- Vitamin K antagonists (VKAs) such as warfarin
- Acquired or congenital coagulation factor disorders
- Vitamin K deficiency
- Liver disease
- Disseminated Intravascular Coagulation (DIC)
- Hemophilias
- Acquired qualitative or quantitative platelet abnormalities
- Embolic strokes
- Sickle Cell Anemia
Other risk factors in the development of intracerebral hemorrhage (ICH) may include:[4]
- High alcohol intake
- Lower cholesterol
- Lower triglycerides
- Older age
- Black ethnicity
New anticoagulant medications such as dabigatran, rivaroxaban, and apixaban appear to be associated with a lower risk of ICH than VKAs. [7]
References
- ↑ 1.0 1.1 Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemor- rhage: a longitudinal population-based study. Stroke. 2011;42:2431– 2435. doi: 10.1161/STROKEAHA.111.615260.
- ↑ 2.0 2.1 Rådberg JA, Olsson JE, Rådberg CT. Prognostic parameters in sponta- neous intracerebral hematomas with special reference to anticoagulant treatment. Stroke. 1991;22:571–576. doi: 10.1161/01.STR.22.5.571.
- ↑ 3.0 3.1 Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–121. doi: 10.1212/01.wnl.0000250340.05202.8b.
- ↑ 4.0 4.1 Ariesen MJ, Claus SP, Rinkel GJ, Algra A (2003). "Risk factors for intracerebral hemorrhage in the general population: a systematic review". Stroke. 34 (8): 2060–5. doi:10.1161/01.STR.0000080678.09344.8D. PMID 12843354.
- ↑ Bos MJ, Koudstaal PJ, Hofman A, Breteler MM (2007). "Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study". Stroke. 38 (12): 3127–32. doi:10.1161/STROKEAHA.107.489807. PMID 17962600.
- ↑ Hackam DG, Mrkobrada M (2012). "Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis". Neurology. 79 (18): 1862–5. doi:10.1212/WNL.0b013e318271f848. PMID 23077009. Review in: Evid Based Ment Health. 2013 May;16(2):54
- ↑ Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of random- ized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70:1486–1490. doi: 10.1001/jamaneurol.2013.4021